SCHEMBL4063305

SCHEMBL4063305

N#CCc1ccc(-c2ncnc3c2ncn3C2CCCCO2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.53
TSHR P16473 1/20 0.53
CYP2C19 P33261 1/20 0.53
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PI4KB Q9UBF8 2/20 0.50
TP53 P04637 1/20 0.50
CYP2C9 P11712 1/20 0.50
NFKB1 P19838 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
APEX1 P27695 1/20 0.50
PI4KA P42356 1/20 0.50
BLM P54132 1/20 0.50
KMT2A Q03164 1/20 0.50
ADCY1 Q08828 1/20 0.50
PI4K2B Q8TCG2 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122030 0.86 NPC1 (0.60) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL4137893 0.84 CYP1A2 (0.54) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL4134543 0.81 CYP2C19 (0.57) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL4067215 0.77 NPC1 (0.57) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL4070092 0.77 NPC1 (0.54) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL22111671 0.76 CYP2C19 (0.51) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL4063885 0.76 CYP1A2 (0.56) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL22111670 0.75 CYP2C19 (0.52) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL14964635 0.74 PI4KA (0.60) CYP1A2TSHRCYP2C19NPC1RAB9A
SCHEMBL114339 0.73 CYP2C19 (0.55) CYP1A2TSHRCYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
EP-2016077-A2 PHARMACEUTICAL COMPOUNDS Astex Therapeutics Limited (GB) 2009-01-21 EP disclosed
WO-2007125315-A2 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253718-A1 Pharmaceutical Compounds GRK3, CNKSR1, CSNK1G3 CYP1A2 1220/4885TSHR 165/4885CYP2C19 1592/4885
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors OXSR1, CDK1, CDK3 CYP1A2 2933/4885TSHR 476/4885CYP2C19 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.